Ross Osborn
Stock Analyst at Cantor Fitzgerald
(0.79)
# 2,868
Out of 4,479 analysts
81
Total ratings
18.03%
Success rate
-15.36%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group | Initiates: Overweight | $11 | $6.73 | +63.57% | 1 | Jul 2, 2024 | |
| ELUT Elutia | Maintains: Overweight | $5 → $11 | $4.45 | +147.19% | 6 | Jun 20, 2024 | |
| NNOX Nano-X Imaging | Reiterates: Overweight | $17 | $7.00 | +142.86% | 7 | May 31, 2024 | |
| VNRX VolitionRx | Reiterates: Overweight | $2.5 | $0.62 | +306.37% | 3 | May 16, 2024 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $44 | $26.98 | +63.08% | 4 | May 15, 2024 | |
| NYXH Nyxoah | Maintains: Overweight | $18 → $17 | $7.03 | +141.82% | 2 | May 15, 2024 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $3 | $0.77 | +290.37% | 3 | May 15, 2024 | |
| XGN Exagen | Maintains: Overweight | $5 → $7 | $1.80 | +288.89% | 4 | May 14, 2024 | |
| RCEL AVITA Medical | Maintains: Overweight | $22 → $21 | $7.75 | +170.97% | 8 | May 14, 2024 | |
| NPCE NeuroPace | Reiterates: Overweight | $18 | $7.30 | +146.74% | 3 | May 9, 2024 | |
| CERS Cerus | Maintains: Overweight | $3 → $4 | $1.70 | +135.99% | 3 | May 3, 2024 | |
| MYNZ Mainz Biomed B.V. | Reiterates: Neutral | n/a | $0.37 | - | 7 | Apr 12, 2024 | |
| AWH Aspira Women's Health | Reiterates: Neutral | $3.3 | $1.07 | +208.41% | 5 | Apr 10, 2024 | |
| PRE Prenetics Global | Maintains: Overweight | $10 → $9 | $5.68 | +58.45% | 5 | Apr 4, 2024 | |
| ORGO Organogenesis Holdings | Reiterates: Overweight | $5 | $2.70 | +85.53% | 2 | Mar 1, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $25 | $12.92 | +93.50% | 7 | Feb 27, 2024 | |
| AXGN AxoGen | Reiterates: Overweight | $12 | $7.53 | +59.43% | 2 | Jan 19, 2024 | |
| ASXC Asensus Surgical | Downgrades: Neutral | n/a | $0.33 | - | 3 | Nov 16, 2023 | |
| PACB Pacific Biosciences of California | Upgrades: Overweight | $14 → $11 | $1.25 | +780.00% | 4 | Oct 31, 2023 | |
| PAVM PAVmed | Reiterates: Neutral | $8.61 | $0.74 | +1,063.51% | 2 | Aug 18, 2023 |
MiMedx Group
Jul 2, 2024
Initiates: Overweight
Price Target: $11
Current: $6.73
Upside: +63.57%
Elutia
Jun 20, 2024
Maintains: Overweight
Price Target: $5 → $11
Current: $4.45
Upside: +147.19%
Nano-X Imaging
May 31, 2024
Reiterates: Overweight
Price Target: $17
Current: $7.00
Upside: +142.86%
VolitionRx
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.62
Upside: +306.37%
Sanara MedTech
May 15, 2024
Reiterates: Overweight
Price Target: $44
Current: $26.98
Upside: +63.08%
Nyxoah
May 15, 2024
Maintains: Overweight
Price Target: $18 → $17
Current: $7.03
Upside: +141.82%
Lucid Diagnostics
May 15, 2024
Reiterates: Overweight
Price Target: $3
Current: $0.77
Upside: +290.37%
Exagen
May 14, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $1.80
Upside: +288.89%
AVITA Medical
May 14, 2024
Maintains: Overweight
Price Target: $22 → $21
Current: $7.75
Upside: +170.97%
NeuroPace
May 9, 2024
Reiterates: Overweight
Price Target: $18
Current: $7.30
Upside: +146.74%
Cerus
May 3, 2024
Maintains: Overweight
Price Target: $3 → $4
Current: $1.70
Upside: +135.99%
Mainz Biomed B.V.
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.37
Upside: -
Aspira Women's Health
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $1.07
Upside: +208.41%
Prenetics Global
Apr 4, 2024
Maintains: Overweight
Price Target: $10 → $9
Current: $5.68
Upside: +58.45%
Organogenesis Holdings
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.70
Upside: +85.53%
SI-BONE
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $12.92
Upside: +93.50%
AxoGen
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $7.53
Upside: +59.43%
Asensus Surgical
Nov 16, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Pacific Biosciences of California
Oct 31, 2023
Upgrades: Overweight
Price Target: $14 → $11
Current: $1.25
Upside: +780.00%
PAVmed
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.74
Upside: +1,063.51%